Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Why It Matters

The accelerated development timeline and expanded cash runway position Xilio to capture market share in next‑generation immuno‑oncology, while growing partnership revenue validates its masking technology platform.

Key Takeaways

• XTX501 IND submission targeted for mid‑2026, Phase 1 later 2026
• Multi‑specific PSMA/STEAP1 T‑cell engager aims to prevent antigen escape
• CLDN18.2 masked engager preclinical data to be shown at AACR
• Cash balance $137.5 million extends runway through 2027
• Collaboration revenue $43.8 million in 2025, AbbVie and Gilead

Pulse Analysis

Xilio Therapeutics is leveraging its clinically validated masking technology to address a key limitation of existing immunotherapies: systemic toxicity. By engineering bispecific agents such as XTX501, which pairs PD‑1 blockade with a masked IL‑2 cytokine, the company aims to concentrate immune activation within the tumor microenvironment. This approach could broaden efficacy to tumors that are refractory to conventional checkpoint inhibitors, opening new therapeutic avenues in lung cancer and beyond.

Beyond XTX501, Xilio’s pipeline features innovative multi‑specific T‑cell engagers that combine tumor‑associated antigen targeting with co‑stimulatory signaling. The PSMA/STEAP1 program targets two prevalent prostate cancer antigens, reducing the risk of antigen‑escape resistance, while the CLDN18.2 initiative expands the platform into gastrointestinal and lung cancers. Presenting preclinical data at the AACR meeting underscores the company’s commitment to scientific transparency and positions it as a thought leader in masked immuno‑oncology.

Financially, Xilio’s cash balance more than doubled year‑over‑year, bolstered by warrant exercises and milestone payments from Gilead and AbbVie. The surge in collaboration revenue to $43.8 million reflects growing confidence from major pharma partners in the masking platform’s commercial potential. With a runway extending into 2027 and a clear roadmap for IND filings and Phase 1 trials, Xilio is well‑placed to attract further investment and accelerate its path toward market‑ready, next‑generation cancer therapies.